Handelsbanken Fonder AB Has $3.10 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Handelsbanken Fonder AB lowered its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 27,100 shares of the company’s stock after selling 200 shares during the quarter. Handelsbanken Fonder AB’s holdings in Vaxcyte were worth $3,097,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Darwin Global Management Ltd. lifted its position in Vaxcyte by 374.3% during the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock worth $187,907,000 after buying an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Capital Research Global Investors grew its stake in shares of Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after purchasing an additional 700,414 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Vaxcyte by 9.9% during the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares during the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in shares of Vaxcyte in the first quarter valued at approximately $39,278,000. Institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PCVX. Leerink Partners increased their price objective on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group lifted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. BTIG Research upped their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Mizuho lifted their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $147.50.

Insiders Place Their Bets

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total value of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $84.26, for a total value of $1,263,900.00. Following the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at approximately $40,351,102.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the sale, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,479,005.02. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,098 shares of company stock worth $7,429,653. Corporate insiders own 3.10% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $111.75 on Wednesday. The stock has a 50-day moving average of $95.66 and a 200-day moving average of $79.73. Vaxcyte, Inc. has a one year low of $44.20 and a one year high of $121.06. The stock has a market cap of $12.47 billion, a PE ratio of -26.11 and a beta of 0.99.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter last year, the business earned ($0.70) earnings per share. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.